טוען...
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
BACKGROUND: In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti‐factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma‐derived, are called factor VIII 'by‐passing�...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2015
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7137678/ https://ncbi.nlm.nih.gov/pubmed/26677005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004449.pub4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|